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We extend Spekreijse’s strategy for analyzing lateral interactions in visual evoked potentials (VEPs) to
clinical neurophysiologic testing of patients with epilepsy. Stimuli consisted of the radial windmill/dart-
board pattern [Ratliff, F., & Zemon, V. (1982). Some new methods for the analysis of lateral interactions
that inﬂuence the visual evoked potential. In: Bodis-Wollner (Ed.), Evoked potentials, Vol. 388. (pp.
113–124). New York: Annals of the New York Academy of Sciences.] and conventional checkerboards.
The fundamental and 2nd-harmonic components of the steady-state responses were used to calculate
indices reﬂecting facilitatory (FI) and suppressive (SI) cortical interactions.
We carried out two studies. In the ﬁrst, VEPs in 38 patients receiving antiepileptic drug (AED) therapy
were compared to those of age-matched controls. For three AEDs (tiagabine, topiramate, and felbamate),
addition of the drug did not change the FI and SI compared to baseline values or those of normal controls.
However, the addition of gabapentin was associated with an increase of the FI, and this change was
reversed when the medication was withdrawn. This suggested a medication-speciﬁc change in cortical
lateral interactions.
The second study focused on the effects of neurostimulation therapy. Eleven epilepsy patients receiving
chronic vagus nerve stimulation (VNS) treatment were tested. By comparing VEPs recorded with the
stimulator on (Stim-ON) and turned off (Stim-OFF) in the same session, we determined that VNS did
not have a short-acting effect on lateral interactions. However, when compared with normal controls,
the VNS patients had a signiﬁcantly smaller SI (p < .05), but no difference in the FI, demonstrating the
presence of a chronic effect. We conclude that with the appropriate stimuli, VEPs can be used as a mea-
sure of cortical lateral interactions in normals and epileptic patients, and demonstrate speciﬁc changes in
these interactions associated with certain treatment modalities.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Our contribution to this volume has its conceptual origins in
Henk Spekreijse’s approach to dissecting the visual evoked poten-
tial into physiologically meaningful components. Achieving a phys-
iologically meaningful analysis is a challenge for any surface-
recorded measure of brain activity. This is particularly so for the vi-
sual evoked response, because the presence of multiple generators
with spatiotemporal overlap deﬁes a direct approach via dipole
modeling and related techniques. In his classical paper (Spekreijse,
van der Tweel, & Zuidema, 1973), Spekreijse provided a proof of
concept of an alternative strategy. He designed pairs of stimuli
for which some mechanisms (those responsive to local luminance)
would respond in an identical fashion, but others (those responsive
to local contrast) would respond in a differential fashion. Compar-
ison of the responses thus isolates only those mechanisms that re-
spond differentially. Subsequently, Zemon and Ratliff (1982)
extended this idea to separate kinds of lateral cortical interactions.ll rights reserved.
Conte).In the work described here, we show that these lateral interactions
can be used as a noninvasive measure of the effect of antiepileptic
treatments.
1.1. VEPs as a diagnostic tool
The visual evoked potential (VEP) has attained clinical validity
as a useful diagnostic tool in the assessment of many ophthalmo-
logical and neurological conditions. In most applications, for exam-
ple, amblyopia (Levi & Manny, 1986; Regan, 1977), glaucoma and
optic neuropathies (Celesia & Kaufman, 1985; Halliday & McDon-
ald, 1977; Towle, Moskowitz, Sokol, & Schwartz, 1983), multiple
sclerosis (Bodis-Wollner, Hendley, Mylin, & Thornton, 1979; Ghi-
lardi et al., 1991; Regan, Milner, & Heron,1977), Parkinson’s disease
(Bandini, Pierantozzi, & Bodis-Wollner, 2001) and retinal patholo-
gies (Celesia, 1982; Regan, 1989), diagnosis rests on analysis of
simple attributes of the VEP waveform such as amplitude and
latency, rather than a detailed analysis of its dynamics. These
dynamics are complex, because the VEP is the net result of mech-
anisms sensitive to luminance, contrast, and spatial pattern, in-
cludes contributions from many classes of neurons in multiple
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& Arezzo, 1988). For this reason, the potential utility of the VEP to
reveal details of neuronal interactions is largely untapped.
One way to address this problem is to exploit the differential
selectivity of neuronal interactions across spatial frequencies. In
this manner, Bodis-Wollner and Yahr (1978) have identiﬁed spe-
ciﬁc processing abnormalities associated with dopaminergic deﬁ-
ciency. However, with typical pattern-reversal stimuli (checks or
gratings), components that are driven by local luminance, local
contrast and pattern information are superimposed, since they
are all activated at each reversal of the checkerboard stimulus. As
Spekreijse, Estevez, and Reits (1977) showed, these components
can be separated via comparison of steady-state responses to
spatially related stimuli in which local luminance changes have
been equated but spatial contrast changes differ. Here, we extend
this strategy to the clinical setting, and use it, along with fre-
quency-domain methods, to identify changes in neural interactions
associated with treatment of epilepsy. This approach (the ‘‘wind-
mill-dartboard” method of Zemon & Ratliff, 1982, 1984) identiﬁes
interactions that are highly local – they are reduced by a small
(2–3 minarc) separation of the stimulus components, correspond-
ing to approximately one cortical hypercolumn (about 0.5 mm)
in human striate cortex (Zemon & Ratliff, 1982). Neurophysiologic
evidence in cat (Ts’o, Gilbert, & Wiesel, 1986; Zemon, Kaplan, &
Ratliff, 1980) and in humans (Zemon & Ratliff, 1984) tells us it is
likely that both excitatory and inhibitory synaptic potentials
contribute to these lateral interactions.
1.2. Intra-cortical inhibition in epilepsy
Our motivation to use the VEP to probe cortical interactions in
epilepsy is the result of two considerations. First, although funda-
mental pathophysiologic mechanisms of epilepsy are largely un-
known, it is widely believed that alterations of intracortical
inhibition are important. In particular, the ‘‘GABA hypothesis” pro-
poses that reduced GABAergic inhibition leads to seizure suscepti-
bility, while enhancement of GABAergic inhibition results in an
antiepileptic effect (De Deyn, Marescau, & Macdonald, 1990; Trei-
man, 2001). Secondly, GABA is critical to the normal selectivity of
visual neurons for orientation, spatial pattern, and motion, and
can modulate the way they combine their visual inputs (Conners,
1992). Moreover, studies in which GABA antagonists are applied
to the cortex demonstrate that it is a major contributor to the vi-
sual evoked potential (Daniels & Pettigrew, 1975; Rose & Blake-
more, 1974; Zemon et al., 1980). For these reasons, it is
reasonable to anticipate that lateral interactions mediated by
GABA will be present in the VEP, and that these may be altered
by epilepsy or its treatment. Here, we test this idea by comparing
VEP measures of lateral interactions in patients undergoing two
forms of treatment for epilepsy, antiepileptic drugs (AEDs) and va-
gus nerve stimulation (VNS).
1.3. Epilepsy treatment modalities
AED therapy is the ﬁrst-line treatment for epilepsy, and results
in satisfactory seizure control in approximately 60–70% of patients,
depending on seizure type (Kwan & Brodie, 2000). However, AED
treatment for epilepsy can be limited by toxicity, tolerability, and
incomplete effectiveness. This has motivated the development of
neurostimulation therapies for refractory epilepsy. The ﬁrst clinical
trials using vagus nerve stimulation (VNS) began in 1988, and,
since its U.S. approval in 1997, it has been employed in more than
25,000 epilepsy patients worldwide, with substantial effectiveness.
Approximately 57% of patients have seizure rates reduced by 50%
after 1 year of treatment (Ben-Menachem, Hellstroem, Waldton,
& Augustinsson, 1999; DeGiorgio et al., 2001; Labar, 2004). VNStreatment is not associated with a development of tolerance over
time (Ben-Menachem et al., 1999; Uthman et al., 2004) and VNS
responders maintain signiﬁcant reductions in seizure rates in the
long term (Janszky et al., 2005; Labar, 2004; Uthman et al.,
2004). Very few patients become seizure-free, however, or are able
to reduce or eliminate their medication entirely (Labar & Ponticel-
lo, 2003). Additional studies suggest that efﬁcacy of VNS treatment
is independent of concomitant antiepileptic medications, and of
the stimulation parameters of the device (DeGiorgio et al., 2001;
Labar, 2002). In patients with generalized epilepsy, responsiveness
to VNS treatment is not predicted by seizure type, or epilepsy class,
but has been associated with an onset of epilepsy at a later age
(Uthman et al., 2004), and temporal lobe foci (Casazza, Avanzini,
Ferroli, Villani, & Broggi, 2006).
The VNS device consists of a programmable pulse generator
(NeuroCybernetic Prosthesis (NCP) System – Cyberonics, Inc.) im-
planted in the chest wall. It is powered by a lithium battery and
connected by bipolar leads to the left vagus nerve. The device is
programmed to deliver a biphasic current that continuously cycles
between on and off periods. While AEDs work at least in part by
modulating intracortical interactions (MacDonald & Kelly, 1994),
the mechanism of action of VNS is unknown. The afferent ﬁbers
stimulated by VNS project mainly to the nucleus of the solitary
tract in the brainstem, and therefore, have many subcortical and
cortical connections, resulting in diffuse effects on many regions
throughout the brain including the dorsal raphe nuclei, locus ceru-
leus, activation of thalamus, entorhinal cortex, orbitofrontal gyri,
and anterior insular cortices (Naritoku, Terry, & Helfert, 1995;
Van Laere, Vonck, Boon, Versijpt, & Dierckx, 2002). Electrophysio-
logic studies of the mechanism of action of VNS in humans have re-
vealed no effect on EEG background (Hammond, Uthman, Reid, &
Wilder, 1992a; Salinsky & Burchiel, 1993) or on standard visual,
auditory, somatosensory, or P300 evoked potentials (Brazdil
et al., 2001; Hammond, Uthman, Reid, & Wilder, 1992b; Uthman
et al., 2004), although reduced spike duration and frequency has
been observed (Koo, 2001) with chronic treatment. In a study of
chemosensation effects with VNS treatment, the authors found
prolonged P2 latencies of the olfactory event related potential
(ERP) during the ON cycle of the stimulator suggesting a modula-
tory effect of VNS (Kirchner et al., 2004). However, none of these
studies were speciﬁcally designed to look for effects of VNS on
cortical lateral interactions, as we do here.2. Methods
2.1. Subjects
Control participants were recruited from our laboratory and the Weill Cornell
Medical College personnel. Study patients were recruited from the outpatient adult
epilepsy population of The Comprehensive Epilepsy Center at New York Presbyter-
ian Hospital. Informed consent was obtained from all participants and both studies
were approved by the Institutional Review Board of Weill Cornell Medical College.
In study 1 (the effect of add-on AEDs), eighteen age-matched normals (10M, 8F;
average age: 37 yrs) served as controls. In study 2 (the effect of VNS), twenty-four
participants (16M, 8F; average age: 34 yrs) served as normal controls. These studies
were conducted several years apart, and, consequently, certain technical details dif-
fered, as described below. All control participants had normal or corrected-to-nor-
mal visual acuities and were free from ophthalmologic disease. All study patients
were considered ‘‘responders” to their respective treatments (AEDs or VNS), in that
their seizures were well controlled at the time of VEP testing.
2.1.1. Patient group 1 – Patients with refractory epilepsy receiving traditional AED
medications
Fifty-ﬁve patients with epilepsy (25M, 30F; average age: 35 yrs) were recruited
from separate double-blinded clinical trials conducted by the Comprehensive Epi-
lepsy Center to determine the efﬁcacy of add-on medications for refractory partial
seizures. Gabapentin (GBP) was added in 24 patients, topiramate (TPM), felbamate
(FBM), or tiagabine (TGB) was added in 14 patients, and 17 patients were lost to
attrition. Baseline AED regimens in these patients included: phenytoin (14
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monly prescribed AEDs. Of the 55 patients, 53% were on AED monotherapy, 42%
were on two medications, and 5% were taking three or more medications for seizure
control. AED dosages were adjusted to maintain serum concentrations within the
therapeutic range. All patients had refractory partial seizures (89% with simple or
complex-partial; 16% complex-partial with secondary generalization). The majority
of the patients (56%) were diagnosed with cryptogenic epilepsy. All patients had vi-
sual acuities, with or without correction, of 20/25 or better OU. VEPs were recorded
at baseline and after add-on AED treatment; VEP recordings during the add-on
phase were obtained from 38 of the 55 patients.
2.1.2. Patient group 2 – Patients receiving adjunctive neurostimulation treatment
Eleven patients (5M, 6F; average age: 39 yrs) undergoing chronic VNS therapy
(3.5–10 yrs) were recruited from the Comprehensive Epilepsy Center practice. This
group only included patients who had a clinical beneﬁt from VNS treatment: a
P50% reduction in seizure frequency compared with pre-VNS seizure frequencies
(9/11 patients) or a decrease in duration and severity of seizures (2/11 patients)
as measured by the Chalfont Seizure Severity Scale (O’Donoghue, Duncan, & Sander,
1996). All patients were on stable, standard AED regimens as well (carbamazepine
(5), levetiracetam (3), phenytoin (2), topiramate (2), lamotrigine (1), primidone (1),
clonazepam (1), valproate (1), and zonisamide (1)). Nine of the 11 (81%) patients
had simple and/or complex-partial seizures; two had primary generalized epilepsy.
VNS settings were as follows: current: 0.25–2.5 mA, pulse frequency: 20–30 Hz,
pulse width: 250–750 ls, on/off cycle: rapid cycling (OFF time 61.8 min) in 10 pa-
tients, standard cycling (OFF time P3 min) in one patient. All patients had normal
fundus exams and visual acuities corrected to 20/40 or better OU. Exclusion criteria
included photosensitive seizures, seizures within 24 h prior to VEP testing, evidence
of occipital lesions on imaging studies, and evidence of ophthalmologic disease.
2.2. Stimuli and apparatus
Stimuli, subtending 8.8  8.8 deg, consisted of the windmill-dartboard patterns
(1.0 deg ring thickness) shown in Fig. 1A, and standard contrast-reversal checker-
boards (0.5 deg check size). Steady-state stimuli were delivered at a contrast of
0.3; transient stimuli were delivered at a contrast of 1.0. Displays were linearized
via lookup tables. Stimuli were presented in randomized order in both studies.
In study 1, the display hardware was a Textronix 608 oscilloscope at a viewing
distance of 57 cm, with a mean luminance 150 cd/m2. The raster (256  256 pixels,
270.3 Hz) was controlled by specialized electronics (Milkman et al., 1980), inter-
faced to a DEC 11/73 computer. Stimulation rates were 4.22 Hz for the steady-state
stimuli (windmill-dartboard and checkerboard) and 1 Hz for the transient record-
ings (checkerboard). Pattern-appearance checkerboard and full-ﬁeld ﬂash were also
used.
In study 2, the display hardware was a Multiscan 17seII monitor (Sony) at a
viewing distance of 100 cm, with a mean luminance of 47 cd/m2. The raster
(640  640, 100 Hz) was controlled by a VSG Series Three (Cambridge Research
Co., UK) programmed in Delphi, housed in a Dell PC. Stimulation rates were
4.19 Hz for the steady-state stimuli and 1.07 Hz for the transient stimuli.
2.3. VEP recording procedures
Scalp signals were obtained with Grass gold-cup electrodes positioned at Oz ()
and Cz (+), with a mastoid ground. EEG activity was ampliﬁed 10,000-fold, ﬁltered
(0.01–100 Hz), and digitized (270.3 Hz, Study 1; 400 Hz, Study 2) synchronously
with the display frame. Electrode impedances were 5–10 kX. Viewing was binocu-
lar and participants were instructed to ﬁxate on a ﬁxation point in the center of the
display. To reduce fatigue, brief breaks were taken when necessary during the
recording sessions. Preliminary artifact rejection (via amplitude bounds) was auto-
mated and applied prior to signal averaging. Raw EEG was monitored by the exper-
imenter and at the end of each trial, the ﬁrst four harmonic components were
calculated on-line and displayed on screen. The initial portion (5 s in Study 1, 2 s
in Study 2) of each trial was discarded to avoid initial transients due to contrast
adaptation and possible eye movements. Sessions were typically one hour in dura-
tion for control subjects and Study 1 patients (AEDs only).
In study 2, two additional electrodes were placed on the neck over the sterno-
cleidomastoid muscle near the surgical scar to monitor the on/off cycling of the VNS
device. VEPs were recorded twice in the same testing session (2–3 h) to obtain re-
sponses with the stimulator turned on (Stim-ON) and off (Stim-OFF). (Temporary
discontinuation of the stimulator for up to one hour poses negligible risks to the pa-
tients. Stimulation is routinely discontinued for up to 12 h for surgery or procedures
without complications. This is because the beneﬁts of VNS therapy are believed to
accumulate over periods of weeks.) The order of testing (Stim-ON then Stim-OFF, or
Stim-OFF then Stim-ON) was counterbalanced across patients. In the Stim-OFF
mode, the pulse generator current was programmed to 0 mA, and we waited one
hour before recording the VEP. To record with the stimulator on, trials were initi-
ated when the stimulator cycled off as evidenced in the EEG tracing. For patients
whose off-cycle was shorter than 48 s (minimum time required to obtain a single
trial), the off-cycle was programmed to 5 min to allow for several trials to be re-corded before the next on-cycling of the device. No changes were made to the
on-cycling time or current. At the end of the testing session, device settings were
programmed back to their original values.
2.4. VEP analysis
Three minutes of averaged EEG were analyzed using a discrete Fourier trans-
form. We focus on the amplitudes and phases of the ﬁrst four harmonics because
the power in higher harmonic components was negligible. Conﬁdence limits of
the Fourier components were determined using the Tcirc2 statistic (Victor & Mast,
1991). This statistic determines whether the responses are signiﬁcantly different
from noise and determines the 95% conﬁdence regions of each harmonic compo-
nent. In Study 1, the analysis epochs used for the Tcirc2 analysis consisted of three
one-minute artifact-free trials. In Study 2, the analysis epochs used for the Tcirc2
analysis consisted of successive 10 s segments of the six 30 s trials, excluding any
segments in which there were artifacts in the EEG signal, or in which the VNS device
cycled on.3. Results
3.1. Normal controls
We begin by illustrating the windmill-dartboard method of iso-
lating intracortical lateral interactions (Ratliff & Zemon, 1982,
1984; Zemon & Ratliff, 1982)with example data from a typical nor-
mal subject. The technique relies on comparing responses to two
stimuli (Fig. 1A). The ﬁrst stimulus (W/D-OFF, left) consists of stea-
dy-state pattern-reversal of the center disk and annulus. This is, in
effect, pattern-reversal modulation of a circular checkerboard. It
elicits a response whose waveform (Fig. 1B, left) is similar to the
waveform elicited by pattern-reversal checks, containing nearly
identical responses at each phase of the reversal.
In the second stimulus (W/D-ON, right), the modulated compo-
nents are the same as in the W/D-OFF stimulus, but two additional
static annuli are present. Reversal of the modulated regions pro-
duces a transition between a ‘‘windmill,” with a small number of
contours, and a ‘‘dartboard,” with a larger number of contours
and edges. The critical feature of the pattern is the change in con-
trast across the borders of the contiguous static and dynamic re-
gions. This stimulus results in a very different response
waveform (Fig. 1B), in which the response to the two stimulus
transitions differs dramatically.
To quantify these waveforms and their differences, we proceed
as illustrated in Fig. 2A. Each stimulus cycle has two transitions.
For each stimulus, we decompose the raw responses into an ‘‘even”
trace that contains components common to the two transitions,
and an ‘‘odd” trace that contains components that differ at the
two transitions. For the W/D-OFF stimulus (ﬁrst column), the even
trace is very nearly identical to the raw trace, and contains the bulk
of the response. For the W/D-ON stimulus (second column), both
the even trace and the odd trace contribute to the response, be-
cause the responses to the two stimulus transitions differ. Note
that the checkerboard-reversal stimulus (third column) elicits a re-
sponse that is similar to the W/D-OFF stimulus.
Next, we quantify the even and odd traces by Fourier analysis.
The even trace, so named because it contains all even Fourier com-
ponents, is dominated by the component at the second harmonic of
the stimulus frequency. The odd trace, so named because it con-
tains all odd Fourier components, is dominated by the component
at the fundamental stimulus frequency. Each of these Fourier com-
ponents can be represented as a vector in the complex plane (Fig.
2B), whose length indicates the size of the response and whose
direction indicates the timing of the response. Addition of the sta-
tic component of the stimulus thus has two robust effects (Fig. 2B).
A fundamental response component is elicited by the W/D-ON
stimulus but not the W/D-OFF stimulus. Additionally, the second
harmonic elicited by the W/D-ON stimulus is smaller than the
second harmonic elicited by the W/D-OFF stimulus. These
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Fig. 1. (A) Windmill–Dartboard stimuli. Left: W/D-OFF. Right: W/D-ON. The modulated regions are identical in the W/D-ON and W/D-OFF conﬁgurations, but the static
component of the pattern is present only in the W/D-ON conﬁguration. Thus, interactions between the modulated and static regions result in differences between the VEP
waveforms that the two stimuli elicit. (B) Averaged steady-state responses elicited by these stimuli from one normal control. Each waveform represents the averaged
response over one cycle of the stimulus. Modulation rate: 4.19 Hz, contrast: 0.3.
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modulated regions of the stimuli. We quantify these differences
via two indices, each calculated from the Fourier components of
the steady-state VEP responses:
 Facilitation Index (FI) = Fundamental (W/D-ON)/2nd Harmonic
(W/D-ON)
 Suppression Index (SI) = 2nd Harmonic (W/D-OFF)/2nd Har-
monic (W/D-ON)
We use ratios, rather than differences, to normalize for overall
response size.
3.1.1. Study 1 – Patients with refractory epilepsy receiving traditional
medications
The purpose of this initial study was 2-fold. Would the VEP indi-
ces of cortical interactions in epilepsy patients be different from
those of normal controls and, if differences existed, could they be
related to speciﬁc AEDs?
3.2. Baseline VEP measures
We found no signiﬁcant differences between the normal con-
trols and 55 patients in response measures of amplitude and la-
tency to the standard pattern-reversal checkerboard and ﬂash
stimuli (p = .9, p = .8, respectively). Facilitation and suppression
indices calculated from responses to the windmill-dartboard pat-
terns were also not signiﬁcantly different from controls. Finally,
there were no signiﬁcant differences in the VEP responses among
the patients when they were grouped according to the three most
commonly taken AED medications: phenytoin (14 patients), car-
bamazepine (29 patients), or valproate (16 patients). Although this
was a small sample size, it suggests that epilepsy per se, as well as
the above medications, do not measurably affect either standard
VEP measures (in agreement with Geller, Hudnell, Vaughn, Mes-
senheimer, & Boyes, 2005), or VEP measures of lateral interactions.
3.3. Introduction of additional medications
After introduction of an additional AED (gabapentin (GBP), topi-
ramate (TPM), felbamate (FBM), or tiagabine (TGB)), standard VEP
measures (amplitudes and latencies to the checkerboard and ﬂash
stimuli) were statistically unchanged. There was, however, a
change in the FI speciﬁc to addition of GBP (dosage range: 500–
3600 mg/day; median dosage: 2400 mg/day).
Distributions of the relevant response components are shown
in Fig. 3. Response amplitudes are typically 3–5 lV. Consistentwith the example subject of Figs. 1 and 2, there is a large funda-
mental response to the W/D-ON stimulus (Fig. 3A), and large sec-
ond harmonic responses to the checkerboard stimulus (Fig. 3C)
and the W/D-OFF stimulus (Fig. 3D) – but the second harmonic
responses to the W/D-ON stimulus are smaller (Fig. 3B). The
amplitude of the fundamental response for GBP patients appears
somewhat larger than that of controls (Figs. 3A, 4 and Table 1).
As measured by the FI, this approaches statistical signiﬁcance
(p = .062). However, there is substantial intersubject variability
in the size of the Fourier components, so a within-patient test
is likely to be more sensitive. Indeed, when responses from
GBP-treated patients are compared to their baseline measures,
the increase in the FI is statistically signiﬁcant (paired t-tests,
p = .016). For a small subset (6) of the GBP-treated patients, we
had the opportunity to repeat VEP testing after GBP treatment
was discontinued. Concomitant AEDs were unchanged during
this time. We found that the facilitation indices decreased to
their pre-GBP treatment values.
For the subgroups of patients who received the three AED’s
other than GBP, there were no statistically signiﬁcant changes in
the FI or the SI. For the subgroup of patients who received GBP,
there was no statistically signiﬁcant change in the SI.
In sum, we found that GBP was associated with an alteration
of the VEP that could be identiﬁed with the windmill-dartboard
stimuli, but not with standard (ﬂash and checkerboard) stimuli.
This alteration of lateral interactions was reversible, and was
not associated with the other three AEDs studied. A regression
analysis showed that the change in the FI associated with GBP
therapy did not correlate with age, gender, etiology of the dis-
ease, baseline medication, or seizure type and frequency.
Regression analysis suggested a dependence of the W/D facilita-
tion index on gabapentin dosage but perhaps due to the small
sample size, this did not reach statistical signiﬁcance. We con-
clude that the FI derived from windmill-dartboard VEPs can
identify a change in cortical interactions in epilepsy patients
that is selectively and reversibly associated with a speciﬁc
AED treatment.
3.3.1. Study 2 – Patients receiving chronic VNS
The basis for the antiepileptic action of chronic vagus nerve
stimulation (VNS) is currently unknown. A general hypothesis is
that chronic VNS changes inhibitory circuitry throughout the cor-
tex in a manner that lessens seizure susceptibility. Our goal was
to determine if chronic VNS treatment has a measurable effect
on the VEP, and if so, to compare it to the changes previously seen
with GBP treatment. Furthermore, to determine if there was a
short-acting component of the effect of VNS therapy on the VEP,
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Fig. 2. (A) VEPs elicited by the windmill/dartboard (W/D-ON and W/D-OFF) and checkerboard stimuli from one normal control (data from Fig. 1B). Averaged waveforms are
separated into even and odd harmonic components. Top row: raw signals, middle: even harmonics, bottom: odd harmonics. The light gray shading in the top row indicates
the un-averaged EEG traces. (B) Fourier components (fundamental and 2nd harmonic) represented as vectors, whose magnitude indicates amplitude and whose direction
indicates response phase. The positive X-axis corresponds to an in-phase response, and counterclockwise rotation corresponds to phase advance.
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recording session.
Fig. 5 illustrates typical responses obtained from two pa-
tients receiving VNS therapy in both the Stimulator on (Stim-
ON) and off (Stim-OFF) conditions. There are no apparent differ-
ences in the responses obtained under these two conditions,
either in the mean waveform, or in the overall variability of
the signals. Thus, artifact-free VEP recordings can be reliably
obtained either with the stimulator inactivated, or during the
periods in between the ordinarily programmed stimulation cy-
cles, and, at least to casual inspection, responses are remarkably
similar.
Fig. 3 shows the Fourier components of the steady-state VEPs
obtained from the VNS patients, and Fig. 6 compares the corre-
sponding FI and SI indices with those of normal controls. We ﬁrst
compare the indices derived from the Stim-ON and Stim-OFF con-
ditions in individual VNS patients (Fig. 6). For each patient, a line
connects the data collected in the Stim-ON (ﬁlled circle) and
Stim-OFF (open circle) conditions. There were no within-subject
differences (two-tailed, paired t-test, p = .4) between responses ob-tained in these two testing conditions. Also (not shown), there
were no differences in the response variance in these two condi-
tions, as measured by Tcirc2. This indicates the lack of a detectable
short-term effect of VNS within individual patients, either on re-
sponse size or its variability.
To look for effects of chronic VNS, we compared indices ob-
tained from Study 2 patients to those of their control group (Ta-
ble 1). This revealed no change in the FI (p = .5), but a signiﬁcant
decrease in the SI (p < .05). Responses to the transient and stea-
dy-state checkerboard stimuli were not signiﬁcantly different
from that of controls, and were unchanged in Stim-ON and
Stim-OFF conditions. Thus, while we identiﬁed an alteration in
lateral interactions in the VNS patient group compared to con-
trols (a decrease in SI), this alteration differed from that of the
GBP group (increase in FI).
We did not identify a signiﬁcant correlation between the size of
the reduction of the SI and age, gender, duration of VNS therapy, or
VNS dose (calculated as duty cycle  current, Harden & Labar,
2000), but the lack of a correlation must be interpreted in view
of the small sample size.
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Table 1
Comparison of group means calculated from the log facilitation and log suppression
indices
Summary of group means Log FI Log SI
Study 1
Controls (n = 18) .24 ± .21 .22 ± .26
GBP Pts (n = 24) .43 ± .29 .20 ± .17
Study 2
Controls (n = 24) .31 ± .20 .34 ± .14
VNS Pts (n = 11)
Stim-ON .27 ± .28 .17 ± .17
Stim-OFF .21 ± .22 .19 ± .19
Study 1: there is no statistical difference (p = .8) in the mean SI for GBP patients
compared with their control group, however, the FI approaches statistical signiﬁ-
cance (p = .06). Study 2: For VNS patients, there was no difference in the indices
calculated in the Stim-ON versus Stim-OFF conditions (p = .4). There was also no
statistical difference (p = .5) in the mean FI for VNS patients compared with their
control group. However, the VNS patients had a signiﬁcantly smaller SI, (p < .05).
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4.1. Summary of ﬁndings
Our main ﬁnding is that Fourier analysis of responses to the
windmill/dartboard stimuli identiﬁes alterations of the VEP associ-ated with speciﬁc antiepileptic therapies. These alterations are not
apparent from standard VEP analysis (i.e., latency and amplitude of
transient checkerboard responses). We quantiﬁed the VEP changes
by two indices, a facilitation index (FI) and a suppression index (SI),
that reﬂect different kinds of lateral interactions that can be teased
out of the VEP response to appropriately chosen stimuli.
In Study 1, which examined AED treatment in 55 patients, we
found a signiﬁcant, reversible augmentation of the FI in patients
receiving add-on GBP medication. This effect appeared to be spe-
ciﬁc to GBP, and was not seen in patients receiving other add-on
AEDs (TPM, FBM, TGB). In Study 2, which examined chronic VNS
treatment in 11 patients, we found a signiﬁcant reduction of the
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VEP’s reliably during intermittent VNS, and that there was no
short-term effect of discontinuing stimulation on the VEP.4.2. Physiological correlates
Previous VEP studies in normal subjects (Zemon & Ratliff, 1982)
indicate that the interactions that contribute to the FI and SI re-
sponse to the windmill/dartboard stimuli reﬂect interactions that
are highly localized in space (2–3 A”), corresponding to approxi-
mately 0.5 mm in visual cortex. Studies in the experimental animal
(Zemon et al., 1980) indicate that GABAergic inhibitory mecha-
nisms are the main contributor to the VEP. Thus, the changes quan-
tiﬁed by the FI and SI most likely are dominated by changes in
GABA-mediated local inhibitory interactions. As we review here,
current views of the likely mechanisms of action of GBP and VNS
are consistent with this idea.
Although gabapentin was designed as a structural analog of
GABA, it does not interact directly with the GABA receptors (Craw-
ford, Ghadiali, Lane, Blumhardt, & Chadwick, 1987). Nevertheless,
several studies suggest that the action of gabapentin is mediated
by GABAergic systems (Leach et al., 1997; MacDonald & Kelly,
1994; Treiman, 2001). Of particular relevance are two studies by
Petroff, Hyder, Rothman, and Mattson (2000), (2006). They found
that GBP increased occipital lobe GABA within 1 h of the ﬁrst dose
in all patients. Additionally, they found that homocarnosine (an
inhibitory neuromodulator hydrolyzed into GABA) and GABA con-
centrations were low in patients who had frequent seizures and
normal in patients with better seizure control. They hypothesized
a mechanistic link; that low homocarnosine and GABA levels con-
tribute to cortical hyperexcitability, allowing for the spread of epi-
leptiform activity.
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increasing GABA-mediated cortical inhibition (Ben-Menachem et
al., 1995, 1999; Marrosu et al., 2003; Rutecki, 1990; Van Laere et
al., 2002). In 2003, Marrosu and co-workers examined the effects
of VNS on cortical GABAA receptor density (GRD) in 10 patients
with partial epilepsy. They found that a reduction in seizure fre-
quency was associated with an increase in GRD to normal values
(r2 = .98; p < .0001) within the ﬁrst year of VNS treatment.
4.3. Future directions
Thus, while the mechanism of the antiepileptic action of GBP
and VNS are both unknown, available evidence suggests that
boosting of GABAergic inhibitory mechanisms plays an important
role. This meshes with our observations of changes in cortical
interactions that are associated with these treatments. It also sug-
gests further directions of study. First, while Study 1 identiﬁes
alterations speciﬁc to GBP (and not some aspect of the epileptic
‘‘state” or the patient population), it is possible that the increased
FI is not simply a drug effect, but rather results from an interaction
of GBP and the disease state. This could be addressed by studying
VEPs of patients who are receiving GBP for other indications,
including chronic neuropathic pain, depression, and migraines
(Pappagallo, 2003; Rogawski & Löscher, 2004). The parallel ques-
tion can be addressed for VNS, since it is now approved for other
indications (e.g., depression). Second, while GBP and VNS both af-
fect lateral interactions in the VEP, the effects are different. This
suggests that these two interventions have effects on different as-
pects of inhibitory circuitry, which could be studied in animal
models. VEP studies cannot address this level of detail, but they
can determine how the effects develop over the course of treat-
ment, an issue that we are now addressing. Finally, future prospec-
tive studies of these VEP measures may provide a way to
determine who is likely to beneﬁt from VNS. This would be of con-
siderable practical value, considering the invasive nature of VNS
and its only partial success rate (Labar, 2004; Uthman et al., 2004).
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